Literature DB >> 6625534

Brainstem glioma: clinical manifestations of meningeal gliomatosis.

R J Packer, J Allen, S Nielsen, C Petito, M Deck, B Jereb.   

Abstract

Brainstem gliomas of children are variably malignant tumors that rarely have been reported to produce subarachnoid dissemination. Nevertheless, during a two-year period, 5 of 15 such patients treated by us developed symptoms of leptomeningeal metastases. The diagnosis of an anaplastic astrocytoma with meningeal gliomatosis was confirmed postmortem in all 5. In 3 children, meningeal symptoms preceded other signs of posterior fossa recurrence. Symptoms of meningeal gliomatosis included local or radiating back pain (5 patients), segmental weakness (3), paresthesia (2), and incontinence (2). Myelography, performed in 4 patients, was the most useful diagnostic technique, disclosing multiple intradural filling defects or a high degree of block in 3 patients. Although the cerebrospinal fluid was abnormal in all 4 examined patients, in only 1 were malignant cells detected. Prolonged survival, which appears to predispose to dissemination of adult malignant gliomas, was not an apparent factor in our patients.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6625534     DOI: 10.1002/ana.410140204

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  19 in total

1.  Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma.

Authors:  Rajni Sethi; Jeffrey Allen; Bernadine Donahue; Matthias Karajannis; Sharon Gardner; Jeffrey Wisoff; Saroj Kunnakkat; Jeena Mathew; David Zagzag; Kia Newman; Ashwatha Narayana
Journal:  J Neurooncol       Date:  2010-07-10       Impact factor: 4.130

2.  Treatment of meningeal gliomatosis.

Authors:  P F Pradat; K Hoang-Xuan; P Cornu; K Mokhtari; N Martin-Duverneuil; M Poisson; J Y Delattre
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

3.  Supratentorial meningeal spread from brainstem glioma.

Authors:  E P Vries; M De Visser; D Troost
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-08       Impact factor: 10.154

4.  Primary spinal leptomeningeal astrocytoma.

Authors:  D A Ramsay; V Goshko; S Nag
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

5.  Incidence and patterns of neuraxis metastases in children with diffuse pontine glioma.

Authors:  Sridharan Gururangan; Colleen A McLaughlin; James Brashears; Melody A Watral; James Provenzale; R Edward Coleman; Edward C Halperin; Jennifer Quinn; David Reardon; James Vredenburgh; Allan Friedman; Henry S Friedman
Journal:  J Neurooncol       Date:  2006-04       Impact factor: 4.130

6.  Primary dissemination of high-grade gliomas in children: experiences from four studies of the Pediatric Oncology and Hematology Society of the German Language Group (GPOH).

Authors:  Martin Benesch; Sabine Wagner; Frank Berthold; Johannes E A Wolff
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

Review 7.  Primary diffuse leptomeningeal gliomatosis with anaplastic features.

Authors:  M T Giordana; G B Bradac; C A Pagni; S Marino; A Attanasio
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

8.  Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma.

Authors:  Fumiyuki Yamasaki; Kaoru Kurisu; Yoshinori Kajiwara; Yosuke Watanabe; Takeshi Takayasu; Yuji Akiyama; Taiichi Saito; Ryosuke Hanaya; Kazuhiko Sugiyama
Journal:  Neuro Oncol       Date:  2011-06-08       Impact factor: 12.300

Review 9.  Primary diffuse leptomeningeal gliomatosis (PDLG): a neoplastic cause of chronic meningitis.

Authors:  P Y Dietrich; M S Aapro; A Rieder; G P Pizzolato
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

10.  Cerebrospinal metastases in malignant childhood astrocytomas.

Authors:  R S Kandt; S Shinnar; B J D'Souza; H S Singer; M D Wharam; P K Gupta
Journal:  J Neurooncol       Date:  1984       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.